



**Corporate Social Responsibility: bioMérieux fulfills the criteria of the Science Based Targets initiative (SBTi), becomes listed in the Dow Jones Sustainability Index (DJSI) and maintains its 1<sup>st</sup> place in the Euronext Vigeo Eiris Index**

Marcy l'Étoile, France – December 14<sup>th</sup>, 2021 – bioMérieux, a world leader in the field of *in vitro* diagnostics, recently received a series of official recognitions for its achievements in Corporate Social Responsibility (CSR) from independent third parties. These included approval of bioMérieux's greenhouse gas emissions reduction targets by the Science Based Targets initiative (SBTi), inclusion in the Dow Jones Sustainability Index (DJSI) at both World and European levels, and the renewal of its leading position in its sector in the Euronext Vigeo Eiris Index.

These acknowledgements illustrate the successful integration of the Company's CSR ambitions into the corporate strategy with the ultimate objective to support the United Nations Sustainable Development Goals.

Since its foundation in 1963, bioMérieux has aspired to continuously expand its social, societal and environmental commitment around the world. In early 2021, the Company developed a new in-depth CSR strategy that strengthened its ambition to be an integral part of bioMérieux's global strategy and built around 5 pillars: *Health, Planet, Healthcare Ecosystem, Employees, and Extended Company*.

Our long-term commitment to sustainability has recently been recognized by major international organizations:

- **The Science Based Targets initiative (SBTi) approves bioMérieux's objectives:**

bioMérieux's emissions reduction targets and approach have been approved by the Science Based Targets initiative as consistent with the levels required to meet the goals of the Paris Climate Agreement, and to keep global warming to 1.5°C, which, according to the latest climate science, is needed to prevent the most damaging effects of climate change.

- **The Dow Jones Sustainability Index includes bioMérieux for the first time:**

bioMérieux has qualified as a constituent of the Dow Jones Sustainability World and Europe Indices. The DJSI is a float-adjusted market capitalization weighted index that measures the performance of companies selected using environmental, social and governance (ESG) criteria.

Manjit Jus, Global Head of ESG Research, S&P Global said: "*We congratulate bioMérieux for being included in the Dow Jones Sustainability Index (DJSI) for Health Care Equipment & Services. A DJSI distinction is a reflection of being a sustainability leader in your industry. The record number of companies participating in the 2021 [S&P Global Corporate Sustainability Assessment](#) is testament to the growing movement for ESG disclosure and transparency.*"



- **Ranked #1 of its category in the Euronext Vigeo Eiris Index:**

The extra-financial rating agency Vigeo Eiris (V.E) ranks bioMérieux No.1 of 47 companies in the Health Care Equipment & Services sector in its ESG assessment. bioMérieux improved its score by 3 points compared to 2020, when it already occupied first place.

All sectors combined, bioMérieux is in the top 6% of all companies assessed by V.E, a Moody's Corporation subsidiary.

*“Corporate Social Responsibility (CSR) has been in the DNA of bioMérieux since its creation. I am deeply convinced that our Company has an important role to play for today’s society as well as for future generations, alongside our public health mission and beyond generating profits. By establishing ambitious social, societal and environmental targets at every level of our business, we further strengthen our commitment to improve our impact and help build a healthier world. I am delighted to see that our commitment is acknowledged by such important actors as SBTi, DJSI and Vigeo Eiris.”* declared Alexandre Mérieux, Chairman and CEO, bioMérieux.

[Learn more about bioMérieux’s CSR ambition and other recognitions](#)

*\* The targets covering greenhouse gas emissions from bioMérieux’s operations (scopes 1 and 2) represent an absolute reduction of more than 50% in 2030 compared with 2019. bioMérieux’s targets for the emissions from its value chain (scope 3) also meet the SBTi’s criteria for ambitious value chain goals, meaning they are in line with current best practices. Scope 1 emissions are direct emissions from owned or controlled sources. Scope 2 emissions are indirect emissions from the generation of purchased energy. Scope 3 emissions are all indirect emissions (not included in scope 2) that occur in the value chain of the reporting company, including both upstream and downstream emissions. (Source: [Greenhouse Gas Protocol](#))*

## ABOUT BIOMÉRIEUX

### *Pioneering Diagnostics*

A world leader in the field of *in vitro* diagnostics for over 55 years, bioMérieux is present in 44 countries and serves more than 160 countries with the support of a large network of distributors. In 2020, revenues reached €3.1 billion, with over 90% of international sales (outside of France).

bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.



bioMérieux is listed on the Euronext Paris stock market.

Symbol: BIM – ISIN Code: FR0013280286

Reuters: BIOX.PA/Bloomberg: BIM.FP

Corporate website: [www.biomerieux.com](http://www.biomerieux.com). Investor website: <https://www.biomerieux.com/en/finance>



## CONTACTS

### *Investor Relations*

**bioMérieux**

Franck Admant

Tel.: +33 (0)4 78 87 20 00

[investor.relations@biomerieux.com](mailto:investor.relations@biomerieux.com)

### *Media Relations*

**bioMérieux**

Romain Duchez

Tel.: +33 (0)4 78 87 21 99

[media@biomerieux.com](mailto:media@biomerieux.com)

### **Image Sept**

Laurence Heilbronn

Tel.: +33 (0)1 53 70 74 64

[lheilbronn@image7.fr](mailto:lheilbronn@image7.fr)

Claire Doligez

Tel.: +33 (0)1 53 70 74 48

[cdoligez@image7.fr](mailto:cdoligez@image7.fr)

PRESS RELEASE